Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer ... Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma (ACC), T-cell Acute Lymphoblastic Leukemia (T-ALL), and Desmoid Tumors. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0781 | -74.3101807802 | 0.1051 | 0.1051 | 0.027 | 1205 | 0.05750731 | CS |
4 | 0 | 0 | 0.027 | 0.1051 | 0.027 | 1352 | 0.03687377 | CS |
12 | 0.007 | 35 | 0.02 | 0.1051 | 0.02 | 1390 | 0.04522291 | CS |
26 | -0.273 | -91 | 0.3 | 0.3196 | 0.0012 | 4511 | 0.18415941 | CS |
52 | -0.763 | -96.582278481 | 0.79 | 1.49 | 0.0012 | 11795 | 0.7146646 | CS |
156 | -4.963 | -99.4589178357 | 4.99 | 4.99 | 0.0012 | 158729 | 0.17610268 | CS |
260 | -0.108 | -80 | 0.135 | 4.99 | 0.0012 | 158030 | 0.17610268 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales